Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
NUFS(TM) (Nanoparticulation Using Fat and Supercritical Fluid)_Bio-Synectics Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
The NUFSTM is a drug delivery platform technology enabling efficient and effective formulation of poorly soluble drug substances. It generates nanoparticles of poorly water soluble substances by utilizing edible solid lipids and the supercritical fluid of...
Contact Heajin Jung
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
The NUFSTM technology is composed of the following two steps. [Step 1] The nanoparticles of an active ingredient are generated within the mixture of solid lipids [Step 2] By appl

- The NUFSTM is a drug delivery platform technology enabling efficient and effective formulation of poorly soluble drug substances. It generates nanoparticles of poorly water soluble substances by utilizing edible solid lipids and the supercritical fluid of CO2.

- The nanoparticulate form of poorly soluble substances generated by the NUFSTM process can be conveniently used for various drug formulations such as oral, intravenous, inhalable, topical, and so on.

- The example of reformulation of SINGULAIR®(montelukast sodium) as a nanoparticulate free base form shows that the the NUFSTM technology can be used to decrease the inter-individual drug absorption variances and shorten the time for drug absorption not only to enhance the bioavailability.

- We applied the NUFSTM technology to develop the toxic surfactant free form docetaxel (NufsDTXTM). By performing various animal test we confirmed that NufsDTXTM has the similar anti-cancer efficacy with the original drug TAXOTERE® and as can be seen in the following pictures the reformulation provides very low toxicity profiles compared to the TAXOTERE®.


- In case of oral formulation the technology can be very helpful for solving the problems caused by the poor solubility of drug substances such as poor bioavailability, inter-individual variances, and fed-fasted variances.

- The technology enables convenient intravenous formulations by only nanoparticulate dispersions of drug substances. So it can be used for the reformulation of chemotherapy drugs with harsh surfactants in order to remove the problem of hypersensitivity.

(1) A platform technology applicable to many poorly soluble substances
- The competing nanoparticulation technology, wet-milling is known to have the concern of possible contamination from milling media making it difficult to be used for intravenous injectables. But the NUFS TM process can be used for various formulations such as oral, injectable, inhalable, topical, and so on.

(2) No safety concern on the carrier
- The NUFS TM process only uses FDA approved inactive ingredients without using any special
carriers to make nanoparticles.

(3) Superior nanoparticle characteristics
- The [Figure 1] below shows the example of nanoparticulation using itraconazole. The NUFS TM
process typically produces very narrowly distributed particles in the range of 100nm~300nm.

(4) Easy and cost-effective process
- As we can get a powder form as the direct output from the NUFSTM process there is no need for
drying steps which are typically needed for other technologies such as wet-milling and high
pressure homogenization.
- The technology can be easily incorporated into the cGMP requirements.


Key words:
Drug Delivery, Nanoparticle, Nano Drug Delivery, Nanoparticulation, Drug Formulation, Docetaxel, Docetaxel nanoparticle, Taxane nanoparticle

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out licensing / Collaboration
FEATURED
Last Updated Jun 2016
Technology Type PLATFORM
Phase of Development PRECLINICAL
GOVERNMENT INSTITUTE